Contrast-induced nephropathy: do statins offer protection?

Sadat, Umar

doi:10.1097/hco.0b013e3283470340

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various drugs have been assessed as prophylactic nephroprotective agents against contrast-induced acute kidney injury (CI-AKI) such as N-acetylcysteine (NAC) [36,83], statins [84,85], ascorbic acid [76,86], and theophylline [87]. However, only statins have been approved for the prevention against the occurrence of CIN.…”

Section: Pharmacological Prophylaxismentioning

confidence: 99%

See 1 more Smart Citation

Contrast-Induced Nephropathy

Elserafy¹,

Abdel-Salam²

2020

New Insight Into Cerebrovascular Diseases - An Updated Comprehensive Review

View full text Add to dashboard Cite

With the worldwide increase in the incidence of atherosclerotic coronary artery disease, the rate of coronary interventions has increased. One of the serious complications of this procedure is contrast-induced nephropathy (CIN). This complication can lead to poor outcomes, with an increase in morbidity and mortality of patients. The pathophysiology and risk factors for the occurrence of contrast-induced nephropathy are several and interconnected. The most proposed management of this entity is prophylaxis and thus avoidance of its occurrence. We will take a deeper look on the pathophysiology, the mechanisms by which this complication is aggravated, and how to expect and manage such a problem.

show abstract

Section: Pharmacological Prophylaxismentioning

confidence: 99%

“…However, only statins have been approved for the prevention against the occurrence of CIN. Currently, the CM safety committee recommends the withdrawal of nephrotoxic drugs before CM administration [85].…”

Section: Pharmacological Prophylaxismentioning

confidence: 99%

Contrast-Induced Nephropathy

Elserafy¹,

Abdel-Salam²

2020

New Insight Into Cerebrovascular Diseases - An Updated Comprehensive Review

View full text Add to dashboard Cite

show abstract

“…Various drugs have been assessed as prophylactic nephroprotective agents against CI-AKI such as N-acetylcysteine (NAC) [71, 186], statins [187, 188], ascorbic acid [189–194], and theophylline [195]. But none of these have so far been approved for the prevention of CI-AKI.…”

Section: Prevention Of Ci-akimentioning

confidence: 99%

Radiographic Contrast-Media-Induced Acute Kidney Injury: Pathophysiology and Prophylactic Strategies

Sadat

2013

ISRN Radiology

Self Cite

View full text Add to dashboard Cite

Contrast-induced acute kidney injury (CI-AKI) is one of the most widely discussed and debated topics in cardiovascular medicine. With increasing number of contrast-media- (CM-) enhanced imaging studies being performed and growing octogenarian population with significant comorbidities, incidence of CI-AKI remains high. In this review, pathophysiology of CI-AKI, its relationship with different types of CM, role of serum and urinary biomarkers for diagnosing CI-AKI, and various prophylactic strategies used for nephroprotection against CI-AKI are discussed in detail.

show abstract

“…A number of retrospective and prospective studies have demonstrated the potential protective effect of statins on CIN (9)(10)(11). In addition, statins have been reported to exhibit antioxidant effects through decreasing the mRNA expression of NOX4 and p22phox (12,13).…”

Section: Introductionmentioning

confidence: 99%

Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells

Liu

Lei

Duan

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Contrast media (CM)-induced nephropathy (CIN) is a serious complication of intravascularly applied radiocontrast media. At present, no drugs have been approved for the prevention of CIN. The present study aimed to explore the effects and potential mechanisms of atorvastatin on iodinated CM-induced cytotoxicity in the human proximal renal tubular epithelial cells. The cytotoxic effect of iohexol (50, 100 and 200 mg I/ ml) and the protective effect of atorvastatin pretreatment (1, 20 and 40 µM) were assessed. The cytotoxicity of iohexol was evaluated via the MTT cell viability and lactate dehydrogenase assays. The amount of apoptotic cells was determined by flow cytometry. Morphological changes in HK-2 cells were observed via transmission electron microscopy. The mRNA expression of NOX4 and p22phox was measured through reverse transcription-quantitative polymerase chain reaction analysis. The cytotoxicity was induced by iohexol in HK-2 cells. Atorvastatin was identified to significantly alleviate the suppression of cell viability induced by iohexol. Notably, 40 µM atorvastatin also significantly reduced the mRNA expression of intracellular NOX4 and p22phox, and the percentage of apoptotic cells. Furthermore, morphological changes characteristic of injured cells were alleviated by atorvastatin pretreatment. These results suggest that atorvastatin exhibits a protective effect on HK-2 cells against iohexol-induced cytotoxicity through the downregulation of NOX4 and p22phox. Thus, atorvastatin is a potential therapeutic agent for the prevention of CIN and required further study.

show abstract

Contrast-induced nephropathy: do statins offer protection?

Cited by 5 publications

References 22 publications

Contrast-Induced Nephropathy

Contrast-Induced Nephropathy

Radiographic Contrast-Media-Induced Acute Kidney Injury: Pathophysiology and Prophylactic Strategies

Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells

Contact Info

Product

Resources

About